- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-3305
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Schistosomiasis vaccines: where do we stand? ; volume:9 ; number:1 ; day:30 ; month:9 ; year:2016 ; pages:1-15 ; date:12.2016
Parasites & vectors ; 9, Heft 1 (30.9.2016), 1-15, 12.2016
- Urheber
-
Tebeje, Biniam Mathewos
- Beteiligte Personen und Organisationen
-
Harvie, Marina
You, Hong
Loukas, Alex
McManus, Donald P.
SpringerLink (Online service)
- DOI
-
10.1186/s13071-016-1799-4
- URN
-
urn:nbn:de:1111-20161101650
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tebeje, Biniam Mathewos
- Harvie, Marina
- You, Hong
- Loukas, Alex
- McManus, Donald P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?
EU-China trade relations : Where do we stand, where should we go?
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?
EU-China trade relations : Where do we stand, where should we go?
Scabies vaccines: where we stand and challenges ahead
ColVI myopathies: where do we stand, where do we go?
Toxoplasmosis vaccines: what we have and where to go?
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
Organizational learning: Where do we stand? Where do we want to go?
NISQ computing: where are we and where do we go?
Future perspectives on swine viral vaccines: where are we headed?
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?
Nanoparticles in the environment: where do we come from, where do we go to?